P1115: A MULTICENTER PHASE 1/2 TRIAL OF EO2463, A MICROBIAL-DERIVED PEPTIDE THERAPEUTIC VACCINE, AS MONOTHERAPY AND IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB, FOR TREATMENT OF PATIENTS WITH INDOLENT NHL
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 1005-1006
10.1097/01.hs9.0000847328.48663.29